Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Entera Bio Ltd. stock logo
ENTX
Entera Bio
$1.73
-6.0%
$1.98
$1.41
$2.79
$83.63M1.4667,085 shs19,053 shs
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
$0.77
$0.77
$0.67
$3.77
$3.37M1.12N/AN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
$2.07
+2.5%
$1.74
$0.87
$9.25
$67.81M0.25844,430 shs1.59 million shs
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
$4.46
+2.4%
$4.50
$3.03
$14.80
$3.98M1.27138,054 shs9,087 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Entera Bio Ltd. stock logo
ENTX
Entera Bio
-5.72%-11.28%-17.62%+2.37%-3.89%
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
0.00%0.00%0.00%0.00%-37.30%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
+2.48%+14.36%+15.64%+50.00%-72.80%
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
+2.44%+1.27%-2.28%+21.92%-6.39%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Entera Bio Ltd. stock logo
ENTX
Entera Bio
2.7124 of 5 stars
3.55.00.00.02.60.80.0
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
2.3573 of 5 stars
3.44.00.00.02.30.00.6
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
0.1854 of 5 stars
0.02.00.00.02.70.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Entera Bio Ltd. stock logo
ENTX
Entera Bio
3.00
Buy$10.00478.03% Upside
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
0.00
N/AN/AN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
2.80
Moderate Buy$9.60363.77% Upside
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest OTLK, ENTX, TTNP, and GENE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/6/2025
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$24.00 ➝ $21.00
5/20/2025
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Entera Bio Ltd. stock logo
ENTX
Entera Bio
$180K436.83N/AN/A$0.23 per share7.52
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
$7.66M0.44N/AN/A$0.25 per share3.06
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/AN/AN/AN/A($3.09) per shareN/A
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
$180K22.53N/AN/A$2.67 per share1.67
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Entera Bio Ltd. stock logo
ENTX
Entera Bio
-$9.54M-$0.26N/AN/AN/A-4,525.11%-95.10%-82.77%8/8/2025 (Estimated)
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
-$7.88MN/A0.00N/AN/AN/AN/A7/28/2025 (Estimated)
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-$75.37M-$0.91N/AN/AN/AN/AN/A-271.12%8/13/2025 (Estimated)
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
-$4.71M-$4.59N/AN/AN/A-145.92%-129.20%8/13/2025 (Estimated)

Latest OTLK, ENTX, TTNP, and GENE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/8/2025Q2 2025
Entera Bio Ltd. stock logo
ENTX
Entera Bio
-$0.11N/AN/AN/AN/AN/A
5/15/2025Q2 2025
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-$0.55-$0.40+$0.15-$1.50$0.70 millionN/A
5/14/2025Q1 2025
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
N/A-$0.62N/A-$0.62N/AN/A
5/9/2025Q1 2025
Entera Bio Ltd. stock logo
ENTX
Entera Bio
-$0.07-$0.06+$0.01-$0.06N/A$0.04 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Entera Bio Ltd. stock logo
ENTX
Entera Bio
N/AN/AN/AN/AN/A
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
N/AN/AN/AN/AN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/AN/AN/AN/AN/A
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Entera Bio Ltd. stock logo
ENTX
Entera Bio
N/A
13.07
13.07
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
0.01
0.88
0.83
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/A
0.72
0.57
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
N/A
7.73
7.73

Institutional Ownership

CompanyInstitutional Ownership
Entera Bio Ltd. stock logo
ENTX
Entera Bio
14.11%
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
0.63%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
11.20%
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
31.49%

Insider Ownership

CompanyInsider Ownership
Entera Bio Ltd. stock logo
ENTX
Entera Bio
10.38%
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
6.46%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
4.80%
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
0.72%
CompanyEmployeesShares OutstandingFree FloatOptionable
Entera Bio Ltd. stock logo
ENTX
Entera Bio
2045.45 million40.73 millionOptionable
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
504.41 million4.53 millionOptionable
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
2033.57 million31.96 millionOptionable
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
10910,000907,000Optionable

Recent News About These Companies

Titan Pharmaceuticals Inc (TTNP) - Investing.com
Titan Pharmaceuticals: Q4 Earnings Snapshot
Titan Pharmaceuticals receives Nasdaq notice of non-compliance
Titan Pharmaceuticals, Inc. (TTNP)
(TTNP) Technical Pivots with Risk Controls
When (TTNP) Moves Investors should Listen

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Entera Bio stock logo

Entera Bio NASDAQ:ENTX

$1.73 -0.11 (-5.98%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$1.78 +0.05 (+2.89%)
As of 07/11/2025 07:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Genetic Technologies stock logo

Genetic Technologies NASDAQ:GENE

$0.76 0.00 (0.00%)
As of 05/20/2025

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates through AffinityDNA, EasyDNA, and GeneType/Corporate segments. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, type 2 diabetes, pancreatic cancer, melanoma, and atrial fibrillation. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne for the development and commercialization of a novel colorectal cancer risk assessment test; and Memorial Sloan Kettering Cancer Center of New York and University of Cambridge, that assess the conflict among BRCA mutation carriers considering preventive surgery. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

Oncobiologics stock logo

Oncobiologics NASDAQ:OTLK

$2.07 +0.05 (+2.48%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$2.09 +0.02 (+0.97%)
As of 07/11/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Titan Pharmaceuticals stock logo

Titan Pharmaceuticals NASDAQ:TTNP

$4.46 +0.11 (+2.44%)
Closing price 07/11/2025 03:58 PM Eastern
Extended Trading
$4.38 -0.08 (-1.71%)
As of 07/11/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.